Eli Lilly opposes the White House’s push to codify ‘most favored nation’ drug pricing, Lilly CEO Dave Ricks stated in an interview with CNBC.

Lilly is one of more than a dozen pharmaceutical companies that have signed MFN deals with the Trump administration.

Ricks stated Lilly will adopt all its tools to oppose terrible policy, and he thinks this is unfavorable policy.

Eli Lilly opposes the White House’s push to codify “most favored nation” drug pricing into law, CEO Dave Ricks stated in an interview with CNBC. Furthermore, experts in bear market note the continued relevance.

Lilly is one of more than a dozen drugmakers that signed deals with the Trump administration last year agreeing to charge similar prices for prescription drugs in the U.S. as in other wealthy nations. President Donald Trump has long complained that Americans pay high prices to subsidize low prices for medicine in the rest of the international community.

The pharmaceutical industry thought the agreements would pacify those concerns and thwart attempts to generate “most favored nation” pricing the law. But the White House in recent months has pushed Congress to codify elements of the deals. The draft text hasn’t been shared publicly, though the administration has mentioned it’s trying to get pharmaceutical companies to back the effort.

Lilly doesn’t support it, Ricks stated.

“When you throw it into the congressional process, what goes in is not what’s going to come out,” Ricks mentioned. “And I think we see a lot of the public who would rather reduce prices today and not worry about whether we have any recent medicines tomorrow, not worry about whether America will have a robust drug industry and we’ll be able to do research in this country. And I worry about those things, so I don’t think that’s a great idea, and we’ve been pretty clear with the administration and the congressional leaders about that.”

Ricks stated he thinks the Trump administration and leadership on the Hill are listening to the company’s concerns, but he stated Lilly will adopt “all the tools we have to combat terrible policy, and we think it would be terrible policy.” This also touches on aspects of investors.